NVCR - Novocure Ltd Stock Price, Fair Value and News

19.03USD+0.38 (+2.04%)Market Closed

Market Summary

USD19.03+0.38

Market Closed

2.04%

NVCR Alerts

Big jump in Earnings (Y/Y)

Losses in recent quarter

NVCR Stock Price

View Fullscreen

NVCR RSI Chart

NVCR Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

-12.18

Price/Sales (Trailing)

3.74

EV/EBITDA

-17.39

Price/Free Cashflow

-19.68

NVCR Price/Sales (Trailing)

NVCR Profitability

Operating Margin

75.82%

EBT Margin

-25.66%

Return on Equity

-46.63%

Return on Assets

-13.92%

Free Cashflow Yield

-5.08%

NVCR Fundamentals

NVCR Revenue

Revenue (TTM)

550.0M

Rev. Growth (Yr)

19.28%

Rev. Growth (Qtr)

8.56%

NVCR Earnings

Earnings (TTM)

-168.7M

Earnings Growth (Yr)

41.87%

Earnings Growth (Qtr)

13.89%

Breaking Down NVCR Revenue

Last 7 days

3.4%

Last 30 days

4.8%

Last 90 days

50.6%

Trailing 12 Months

-43.9%

How does NVCR drawdown profile look like?

NVCR Financial Health

Current Ratio

6.46

Debt/Equity

1.57

Debt/Cashflow

-0.12

NVCR Investor Care

Shares Dilution (1Y)

1.32%

Diluted EPS (TTM)

-1.57

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	525.7M	550.0M	0	0
2023	522.5M	507.7M	504.0M	509.3M
2022	537.9M	545.2M	542.6M	537.8M
2021	527.2M	544.8M	545.8M	535.0M
2020	379.8M	409.0M	449.6M	494.4M
2019	269.3M	294.5M	321.8M	351.3M
2018	194.3M	217.4M	232.1M	248.1M
2017	104.7M	125.2M	153.6M	177.0M
2016	40.9M	52.3M	65.0M	82.9M
2015	19.9M	24.3M	28.7M	33.1M
2014	0	0	12.9M	15.5M
2013	0	0	0	10.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

CEO	Mr. Asaf Danziger
WEBSITE	novocure.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	1320

Novocure Ltd Frequently Asked Questions

What is the ticker symbol for Novocure Ltd? What does NVCR stand for in stocks?

NVCR is the stock ticker symbol of Novocure Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Novocure Ltd (NVCR)?

As of Fri Jul 26 2024, market cap of Novocure Ltd is 2.06 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NVCR stock?

You can check NVCR's fair value in chart for subscribers.

Is Novocure Ltd a good stock to buy?

The fair value guage provides a quick view whether NVCR is over valued or under valued. Whether Novocure Ltd is cheap or expensive depends on the assumptions which impact Novocure Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NVCR.

What is Novocure Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, NVCR's PE ratio (Price to Earnings) is -12.18 and Price to Sales (PS) ratio is 3.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NVCR PE ratio will change depending on the future growth rate expectations of investors.